Liptruzet Side Effects

Generic Name: atorvastatin / ezetimibe

Note: This document contains side effect information about atorvastatin / ezetimibe. Some of the dosage forms listed on this page may not apply to the brand name Liptruzet.

For the Consumer

Applies to atorvastatin / ezetimibe: oral tablet

Along with its needed effects, atorvastatin/ezetimibe may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking atorvastatin / ezetimibe:

Less Common

• Abdominal or stomach pain
• confusion
• difficult breathing
• difficulty with moving
• irregular heartbeat
• muscle, joint, or bone pain
• muscle stiffness
• muscle weakness
• nausea or vomiting
• nervousness
• numbness or tingling in the hands, feet, or lips
• weakness or heaviness of the legs

Incidence Not Known

• Black, tarry stools
• blistering, peeling, or loosening of the skin
• blood in the urine or stools
• chills
• dark-colored urine
• diarrhea
• fever
• gaseous abdominal or stomach pain
• general tiredness and weakness
• hives, welts, or skin rash
• itching
• large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
• light-colored stools
• severe nausea or vomiting
• sores, ulcers, or white spots in the mouth or on the lips
• swelling of the eyes, face, or inside of the nose
• unsteadiness or awkwardness
• unusual bleeding or bruising
• unusual tiredness or weakness
• yellow eyes and skin

Some side effects of atorvastatin / ezetimibe may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less Common

• Cough
• dizziness
• feeling of warmth
• pain or tenderness around the eyes and cheekbones
• redness of the face, neck, arms, and occasionally, upper chest
• stuffy or runny nose
• sudden sweating
• tightness in the chest

Incidence Not Known

• Being forgetful
• bloating burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• chills
• constipation
• discouragement
• fast heartbeat
• feeling sad or empty
• irritability
• lack of appetite
• loss of interest or pleasure
• loss of memory
• pains in the stomach, side, or abdomen, possibly radiating to the back
• tiredness
• trouble concentrating
• trouble sleeping

For Healthcare Professionals

Applies to atorvastatin / ezetimibe: oral tablet

General

The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.^[Ref]

Hepatic

Common (1% to 10%): ALT increased (5%), AST increased (4%)

Postmarketing reports: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure^[Ref]

Musculoskeletal

Common (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)

Postmarketing reports: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)^[Ref]

Nervous system

Common (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)

Postmarketing reports: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness^[Ref]

Metabolic

Common (1% to 10%): Hyperkalemia (2%)^[Ref]

Endocrine

Common (1% to 10%): Hot flushes (2%)^[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection (5.7%)^[Ref]

Hematologic

Postmarketing reports: Thrombocytopenia, elevated creatine phosphokinase^[Ref]

Hypersensitivity

Postmarketing reports: Anaphylaxis, hypersensitivity reactions^[Ref]

Immunologic

Common (1% to 10%): Influenza (2%)^[Ref]

Respiratory

Common (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)

Postmarketing reports: Interstitial lung disease^[Ref]

Other

Postmarketing reports: Fatigue

Dermatologic

Postmarketing reports: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer